TSE:4552
TSE:4552Pharmaceuticals

JCR Pharmaceuticals (TSE:4552) Q3 EPS Slide Challenges Bullish Profit Recovery Narrative

JCR Pharmaceuticals (TSE:4552) has reported Q3 2026 revenue of ¥8,991 million and basic EPS of ¥0.28, alongside net income excluding extra items of ¥34 million, setting a measured tone for the latest update. The company has seen quarterly revenue move between ¥8,512 million and ¥12,793 million over the past five reported periods, while basic EPS has ranged from a loss of ¥34.28 per share to a profit of ¥18.50 per share, giving investors a clear view of how earnings have been fluctuating...
TSE:4113
TSE:4113Chemicals

Taoka Chemical (TSE:4113) Net Margin Improvement Tests Cautious Earnings Narratives

Taoka Chemical (TSE:4113) has released its Q3 2026 results, reporting revenue of ¥7,687 million and basic EPS of ¥18.77. The company also reported trailing twelve month revenue of ¥32,930 million and EPS of ¥119.55, compared with the prior year period's revenue of ¥29,930 million and EPS of ¥103.15. Over recent quarters, revenue has moved from ¥7,320 million in Q3 2025 to ¥7,687 million in Q3 2026, while basic EPS has shifted from ¥31.27 to ¥18.77 as quarterly earnings recalibrated after a...